<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment and prevention of meningococcal infection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment and prevention of meningococcal infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment and prevention of meningococcal infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Apicella, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allan R Tunkel, MD, PhD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Neisseria meningitidis</em> is an important cause of community-acquired bacterial meningitis and sepsis in children and adults in the United States and in many other countries. (See  <a class="medical medical_review" href="/d/html/1298.html" rel="external">"Epidemiology of Neisseria meningitidis infection"</a> and  <a class="medical medical_review" href="/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis", section on 'Causative organisms'</a> and  <a class="medical medical_review" href="/d/html/1294.html" rel="external">"Epidemiology of community-acquired bacterial meningitis in adults"</a>.)</p><p>The clinical manifestations of meningococcal disease can be quite varied, ranging from transient fever and bacteremia to fulminant disease with death ensuing within hours of the onset of clinical symptoms. (See  <a class="medical medical_review" href="/d/html/1300.html" rel="external">"Clinical manifestations of meningococcal infection"</a>.)</p><p>The treatment and prevention of meningococcal infection will be reviewed here [<a href="#rid1">1-3</a>]. The microbiology, pathobiology, epidemiology, and diagnosis of <em>N. meningitidis</em> infection are discussed separately. (See  <a class="medical medical_review" href="/d/html/1276.html" rel="external">"Microbiology and pathobiology of Neisseria meningitidis"</a> and  <a class="medical medical_review" href="/d/html/1298.html" rel="external">"Epidemiology of Neisseria meningitidis infection"</a> and  <a class="medical medical_review" href="/d/html/1281.html" rel="external">"Diagnosis of meningococcal infection"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TREATMENT OF MENINGITIS AND SEPSIS</span><span class="headingEndMark"> — </span>The treatment of meningococcal sepsis is a complex medical problem, requiring a team approach by physicians skilled in intensive care medicine, infectious diseases, and the management of coagulopathies. Whenever possible, treatment should be given in a facility capable of administering the full range of medical care.</p><p class="headingAnchor" id="H2128584636"><span class="h2">Antibiotic therapy</span></p><p class="headingAnchor" id="H2089800275"><span class="h3">Importance of early administration</span><span class="headingEndMark"> — </span>Invasive meningococcal infection is a medical emergency. Early and appropriate antibiotic treatment markedly improves the outcome of invasive meningococcal infections [<a href="#rid4">4-6</a>]. (See <a class="local">'Prognosis'</a> below.)</p><p>For patients with known or suspected invasive meningococcal infection (patients with severe sepsis syndrome, fever with petechiae and/or ecchymoses, or suspected bacterial meningitis), all attempts should be made to initiate parenteral antibiotics as quickly as possible. Concern for meningococcal disease should be particularly high in the setting of an outbreak or in patients with risk factors for meningococcal disease, such as those with complement deficiencies. (See  <a class="medical medical_review" href="/d/html/1300.html" rel="external">"Clinical manifestations of meningococcal infection"</a> and  <a class="medical medical_review" href="/d/html/1298.html" rel="external">"Epidemiology of Neisseria meningitidis infection", section on 'Risk factors for acquisition of infection'</a>.)</p><p>Advisory groups suggest antibiotics be administered as soon as one hour from the time of presentation given the variability in, and sometimes fulminant, clinical presentation [<a href="#rid7">7,8</a>]. Patients with meningococcal sepsis have extremely high bacterial loads, and increasing bacterial loads have been associated with increased odds of death [<a href="#rid9">9,10</a>]. Given the rapid division time of meningococcus in vitro, a delay of 70 minutes would result in such an increase and a higher risk of a poor outcome. Appropriate parenteral therapy can clear the cerebrospinal fluid (CSF) of meningococci in less than six hours [<a href="#rid11">11</a>].</p><p>Blood cultures should be drawn prior to initiation of antibiotic therapy if possible, but antibiotic therapy should <strong>not</strong> be delayed while waiting for lumbar puncture to be performed. Although administration of antibiotic therapy prior to lumbar puncture can substantially diminish the probability of a positive CSF culture, the diagnosis can often be established from the pretreatment blood cultures and/or polymerase chain reaction (PCR) or other molecular tools. (See  <a class="medical medical_review" href="/d/html/1281.html" rel="external">"Diagnosis of meningococcal infection"</a>.)</p><p>If meningococcal infection is suspected in a physician's office or outpatient clinic, the patient should be stabilized and transported promptly to an appropriate hospital facility. Many experts also suggest giving antibiotics (eg, intramuscular <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>) in the outpatient setting if a patient cannot be transferred within an hour to a hospital but do not delay transfer for antibiotic administration [<a href="#rid12">12,13</a>]. Studies performed during epidemics in the 1990s suggested that administration of antibiotics prior to transfer was associated with improved outcome [<a href="#rid4">4,6</a>]. In addition, a statistical analysis of 125 patients with meningococcal disease who received antibiotic therapy prior to admission (oral or parenteral) suggested that treatment was not harmful and benefitted some less severely ill populations of patients [<a href="#rid14">14</a>].</p><p>Additional care should be taken with infants, for whom an adequate history may not be obtainable. In such situations, direct observation in a controlled setting (eg, emergency room or hospital admission) with empiric treatment until the diagnosis can be excluded is appropriate. (See  <a class="medical medical_review" href="/d/html/6005.html" rel="external">"Bacterial meningitis in the neonate: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Regimen selection</span><span class="headingEndMark"> — </span>In cases of suspected bacterial meningitis, patients should be treated empirically to cover the most likely pathogens while awaiting culture results or molecular diagnostic tests. The following discussion will focus on the treatment of presumed meningococcal infection. Topic reviews that provide a more general overview of initial therapy for bacterial meningitis are presented separately. (See  <a class="medical medical_review" href="/d/html/1290.html" rel="external">"Initial therapy and prognosis of community-acquired bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/d/html/6010.html" rel="external">"Bacterial meningitis in children older than one month: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/6016.html" rel="external">"Bacterial meningitis in the neonate: Treatment and outcome"</a>.)</p><p class="headingAnchor" id="H1065606793"><span class="h4">Therapy pending results of susceptibility testing</span><span class="headingEndMark"> — </span>Intravenous (IV) <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> should be used for treatment of meningococcal meningitis or sepsis pending the results of susceptibility testing. For adults, ceftriaxone is administered as 2 g IV every 12 hours. For children, the dose is 50 mg/kg (maximum 2 g) IV every 12 hours. <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">Cefotaxime</a> can be used instead of ceftriaxone, but this agent is not available in many settings and must be administered more frequently than ceftriaxone.</p><p>Resistance to penicillin is an increasing concern due to the widespread appearance in 2019 of beta-lactamase-containing meningococci that are resistant to penicillin but sensitive to third-generation cephalosporins [<a href="#rid15">15-18</a>]. In one report that evaluated 372 <em>N. meningitidis</em> serogroup isolates in the United States from 2013 to 2020, approximately 9 percent were resistant to penicillin but sensitive to third generation cephalosporins [<a href="#rid15">15</a>]. In another study of 695 meningococcal isolates collected in the United States from 2012 to 2016, all were susceptible to <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a>, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a>, and <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, but approximately 25 percent were penicillin or <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a> intermediate [<a href="#rid18">18</a>]. Although isolates with reduced susceptibility to third generation cephalosporins have been reported, they are less common. In one study from France, invasive meningococcal isolates with reduced susceptibility to third generation cephalosporins represented 2 percent of cases between 2012 and 2015 [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H2219394275"><span class="h4">Therapy based on results of susceptibility testing</span><span class="headingEndMark"> — </span>If susceptibility testing is not reflexively performed, it should be requested. Treatment decisions can be impacted by the appearance of <em>bla</em><sub>ROB-1</sub> beta-lactamase gene containing invasive <em>N. meningitidis</em>, which has been found in the United States and elsewhere [<a href="#rid15">15</a>]<em>. </em>These isolates are penicillin resistant but susceptible to third-generation cephalosporins.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolates susceptible to penicillin</strong> – If susceptibility testing indicates that the isolate is penicillin susceptible (minimum inhibitory concentration [MIC] &lt;0.1 mcg/mL), either <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> or penicillin can be used [<a href="#rid20">20-22</a>]. Ceftriaxone has the advantage of more convenient dosing, but aqueous penicillin IV may be less costly in some cases. If penicillin is selected, patients should undergo subsequent eradication therapy for presumed nasopharyngeal carriage. (See <a class="local">'Eradication of nasal carriage for select patients'</a> below.)</p><p></p><p class="bulletIndent1">If penicillin is used, the typical regimen for adults is <a class="drug drug_general" data-topicid="9749" href="/d/drug information/9749.html" rel="external">penicillin G</a> 4 million units IV every four hours. For children, the dose is 300,000 units/kg per day in a divided dose every six hours; the usual maximum dose is 12 million units/day [<a href="#rid23">23</a>]. Penicillin should <strong>never</strong> be administered intrathecally because of the danger of severe neurotoxicity; in addition, intrathecal therapy is not necessary since both penicillins and cephalosporins readily cross the blood-brain barrier to attain adequate CSF concentrations.</p><p></p><p class="bulletIndent1">The dose of <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> is described above. (See <a class="local">'Therapy pending results of susceptibility testing'</a> above.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">Ceftriaxone</a> and penicillin are bactericidal and have been shown to clear the CSF of viable organisms quickly. They reach levels in the CSF in excess of those needed to treat meningococcus, and the duration of antibiotic activity is prolonged, resulting in stable levels [<a href="#rid24">24,25</a>].</p><p></p><p class="bulletIndent1">However, there are limited clinical data comparing outcomes with penicillin or <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> [<a href="#rid20">20-22</a>]. In an observational study in which most patients received penicillin for four or seven days or ceftriaxone for four days, the overall case-fatality rate was approximately 6 to 7 percent, and the rate of chronic neurologic sequelae was also 6 to 7 percent [<a href="#rid26">26</a>]. These are greatly improved over historical mortality rates prior to the availability of antibiotics. (See <a class="local">'Prognosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolates with reduced susceptibility to penicillin</strong> – If the isolate has reduced susceptibility to penicillin, the approach to treatment depends upon sensitivity to <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most isolates that have reduced susceptibility to penicillin (MIC ≥0.1 mcg/mL) are susceptible to <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>. The dose of ceftriaxone is the same as those used for penicillin-susceptible isolates (2 g IV every 12 hours for adults, or 50 mg/kg (maximum 2 g) IV every 12 hours for children). Although high-dose penicillin may be effective if the penicillin MIC is between 0.1 and 1.0 mcg/mL, ceftriaxone is preferred.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the rare event that the isolate is resistant to both penicillin and <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> can be used if locally available; other possible choices are <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>, a fluoroquinolone such as <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> or <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>, or <a class="drug drug_general" data-topicid="9047" href="/d/drug information/9047.html" rel="external">aztreonam</a> [<a href="#rid27">27</a>], similar to patients who cannot receive a beta-lactam. (See <a class="local">'Patients intolerant of beta-lactams'</a> below.)</p><p></p><p class="bulletIndent1">Relative resistance to penicillin is caused by a reduced binding affinity to specific penicillin-binding proteins [<a href="#rid28">28</a>]. The first reports of <em>N. meningitidis</em> resistant to penicillin appeared in 1988 [<a href="#rid29">29,30</a>].</p><p></p><p class="headingAnchor" id="H2603449448"><span class="h4">Patients intolerant of beta-lactams</span><span class="headingEndMark"> — </span>Systemic meningococcal infection has a high mortality unless treated appropriately. The use of the most effective antibiotics is paramount. Patients who are intolerant to beta-lactams should be managed in consultation with an infectious diseases specialist.</p><p>For such patients, it is important to evaluate the nature of the beta-lactam allergy, since the approach to treatment in these critically ill patients depends upon the type of reaction  (<a class="graphic graphic_algorithm graphicRef112936" href="/d/graphic/112936.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with mild reaction without features of an immunoglobulin (Ig)E-mediated reaction</strong> – In general, most patients who are labeled as allergic to penicillin who do not report a history of severe immediate allergy (eg anaphylaxis) are able to receive a third-generation cephalosporin such as <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>. (See  <a class="medical medical_review" href="/d/html/111361.html" rel="external">"Choice of antibiotics in penicillin-allergic hospitalized patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with IgE-mediated reactions</strong> – Patients with a severe immediate allergy (eg, anaphylaxis) to a penicillin can usually be treated with a third-generation cephalosporin, such as <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, given with a test-dose procedure. (See  <a class="medical medical_review" href="/d/html/111361.html" rel="external">"Choice of antibiotics in penicillin-allergic hospitalized patients", section on 'Test dose procedure (graded challenge)'</a>.)</p><p></p><p class="bulletIndent1">If there is also a history of a severe immediate allergy to <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, most patients can tolerate carbapenems because cross-reactivity rates between penicillins or cephalosporins and carbapenems for patients with proven immediate allergy are &lt;1 percent, although several reactions have been reported [<a href="#rid31">31</a>]. In such patients, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a> should be administered using a test-dose procedure. Carbapenems have been used for bacterial meningitis with meningococcus and other gram-negative organisms, although the experience with meningococcal meningitis is limited [<a href="#rid32">32</a>]. The dose of meropenem recommended for treatment of meningitis is 2 g IV every eight hours for adults or 40 mg/kg every eight hours for children (up to a maximum of 6 g/day) [<a href="#rid32">32</a>]. <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">Imipenem</a> should not be administered, as seizures have been reported with this combination in children [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with serious delayed reactions</strong> – When there is concern for a severe delayed allergy to a penicillin or a cephalosporin (Stevens Johnson syndrome/toxic epidermal necrolysis [SJS/TEN], drug reaction with eosinophilia and systemic symptoms [DRESS], acute generalized exanthematous pustulosis [AGEP]), all beta-lactams and carbapenems should generally be avoided. In this case, <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> (100 mg/kg per day IV in divided doses every six hours, up to a maximum dose of 4 g/day) is an acceptable alternative antibiotic choice, although its availability is limited, particularly in resource-rich settings. Resistance of meningococcal strains to chloramphenicol has rarely been described [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1">Fluoroquinolones are also a potential alternative in patients with meningococcal infection who cannot use beta-lactams or carbapenems. Clinical experience is extremely limited for systemic infection, and the optimal dosing is unclear. As an example, one pharmacokinetic study suggested that in adults, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> 500 mg IV every 12 hours would be sufficient to treat <em>N. meningitidis</em> if the MICs are &lt;0.1 to 0.2 mcg/mL [<a href="#rid35">35</a>]; however, other experts would consider a higher dose of levofloxacin (eg, 750 mg every 12 hours). In either case, the dose may need to be adjusted in patients with known renal insufficiency because of an increased risk of toxicity [<a href="#rid36">36</a>]. Information on renal dosing can be found in the drug information topic within UpToDate.</p><p></p><p class="bulletIndent1">Although fluoroquinolones may be suitable for some patients, resistance to fluoroquinolones is becoming widespread and use of this class of antibiotics should be avoided in areas with known resistance to these agents. Additional information on fluoroquinolone resistance is found below. (See <a class="local">'Regimens'</a> below.)</p><p></p><p class="bulletIndent1">If an agent other than a third-generation cephalosporin is used, patients should undergo subsequent eradication therapy for presumed nasopharyngeal carriage. (See <a class="local">'Eradication of nasal carriage for select patients'</a> below.)</p><p></p><p class="headingAnchor" id="H9"><span class="h3">Duration of therapy</span><span class="headingEndMark"> — </span>An adequate response to therapy includes clearing of fever, stability of blood pressure, improving mental status, and stabilizing of hematologic parameters. A repeat lumbar puncture is not typically required, since the expected clinical improvement is rapid.</p><p>The precise duration of antibiotic therapy will vary based upon the patient's age, the severity of initial illness, and the response to therapy:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adults</strong> – For adults, we suggest a minimum of four days of total therapy for meningococcal meningitis. For patients with a severe presentation and/or delayed response to therapy, extending treatment to seven days is appropriate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children</strong> – For children, we generally treat for five to seven days; this recommendation is consistent with guidelines from the American Academy of Pediatrics [<a href="#rid23">23</a>].</p><p></p><p>Treatment for longer than seven days has not proven necessary unless a secondary infection complicates meningococcal disease.</p><p>Data informing the optimal duration of therapy are limited. In an observational study of 527 cases of invasive meningococcal infection that occurred over a time period when the recommended duration changed from seven to four days, mortality rates and rates of complications were comparable with both durations [<a href="#rid26">26</a>]. Short courses have also been studied in epidemic settings and appear comparably effective to longer courses. (See <a class="local">'Considerations during epidemics in resource-limited settings'</a> below.)</p><p>Previous studies had suggested that seven days was comparable with longer durations, and seven days had been the previously preferred duration [<a href="#rid20">20,37</a>].</p><p class="headingAnchor" id="H2671211237"><span class="h3">Eradication of nasal carriage for select patients</span><span class="headingEndMark"> — </span>Patients with invasive meningococcal disease who were treated with an agent other than a third-generation cephalosporin should receive chemoprophylaxis for eradication of presumed nasopharyngeal carriage prior to discharge from the hospital to prevent subsequent transmission to close contacts [<a href="#rid38">38-40</a>]. Treatment with antimicrobial agents other than third-generation cephalosporins does not reliably eradicate nasopharyngeal carriage of <em>N. meningitidis</em>.</p><p>Chemoprophylaxis regimens for such patients are the same as for post-exposure prophylaxis  (<a class="graphic graphic_table graphicRef51944" href="/d/graphic/51944.html" rel="external">table 1</a>). (See <a class="local">'Regimens'</a> below.)</p><p class="headingAnchor" id="H3669727029"><span class="h3">Considerations during epidemics in resource-limited settings</span><span class="headingEndMark"> — </span>Since 1995, the World Health Organization (WHO) has recommended empiric treatment of suspected cases of meningococcal infection with one or two intramuscular injections of long-acting <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> (oily suspension); however, the continued production of this drug is uncertain. Although alternative drugs with proven efficacy against <em>N. meningitidis</em> are available (eg, benzylpenicillin, <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, and IV or intramuscular chloramphenicol or <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>), protocols requiring multiple injections are impractical during an epidemic.</p><p>Shorter regimens of beta-lactams (eg, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>) are reasonable, cost-effective alternatives [<a href="#rid41">41-43</a>]. As an example, a single intramuscular dose of ceftriaxone is an alternative first-line treatment to <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> for epidemic meningococcal meningitis. In a randomized trial of 510 patients (441 under the age of 15 years) with suspected disease during a meningococcal meningitis epidemic in Niger, a single dose of intramuscular ceftriaxone was as effective as a single dose of long-acting chloramphenicol in oil [<a href="#rid41">41</a>]. The treatment failure rate was 9 percent at three days in both groups and the mortality rate was 5 to 6 percent. Results were similar among patients with confirmed meningitis caused by <em>N. meningitidis</em>.</p><p class="headingAnchor" id="H3159178255"><span class="h2">Discontinuing glucocorticoids</span><span class="headingEndMark"> — </span>Empiric <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> is often administered to adults and children with bacterial meningitis while awaiting microbiologic data. However, the decision to continue dexamethasone treatment for patients who are diagnosed with meningococcal meningitis and sepsis is controversial, since most data supporting the use of dexamethasone has been in persons with confirmed pneumococcal meningitis [<a href="#rid44">44-46</a>]. (See  <a class="medical medical_review" href="/d/html/1299.html" rel="external">"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/d/html/6026.html" rel="external">"Bacterial meningitis in children: Dexamethasone and other measures to prevent neurologic complications"</a>.)</p><p>Many experts discontinue <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> in patients with meningococcal meningitis given the limited data supporting its use. However, others would continue dexamethasone [<a href="#rid47">47</a>], and small case reports have found a reduction in length of hospitalization without an increase in adverse events [<a href="#rid48">48</a>].</p><p>The possible role of pharmacologic doses of glucocorticoids in septic shock and of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> in bacterial meningitis is discussed separately. (See  <a class="medical medical_review" href="/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a> and  <a class="medical medical_review" href="/d/html/1299.html" rel="external">"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/d/html/6026.html" rel="external">"Bacterial meningitis in children: Dexamethasone and other measures to prevent neurologic complications", section on 'Dexamethasone'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Treatment of shock</span><span class="headingEndMark"> — </span>Vascular collapse and shock are frequent early manifestations of meningococcal disease caused largely by the bacterial product lipooligosaccharide, which is a potent toxin. Details of resuscitative efforts for septic shock are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a>.)</p><p class="headingAnchor" id="H3711899698"><span class="h3">Protein C concentrate</span><span class="headingEndMark"> — </span>In severe meningococcal sepsis, protein C activation is impaired [<a href="#rid49">49</a>]. In severe meningococcal sepsis, we suggest use of <a class="drug drug_general" data-topicid="10094" href="/d/drug information/10094.html" rel="external">protein C concentrate</a>, although it has not been approved by the US Food and Drug Administration for this indication. The suggested dose of protein C is 100 to 120 international units/kg initially followed every six hours for three subsequent doses of 60 to 80 international units/kg. (See  <a class="medical medical_review" href="/d/html/1300.html" rel="external">"Clinical manifestations of meningococcal infection"</a>.)</p><p>Limited data suggest that <a class="drug drug_general" data-topicid="10094" href="/d/drug information/10094.html" rel="external">protein C concentrate</a> might be beneficial in patients with meningococcal sepsis and purpura fulminans [<a href="#rid50">50</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial including 40 children with purpura fulminans and meningococcal sepsis, treatment with <a class="drug drug_general" data-topicid="10094" href="/d/drug information/10094.html" rel="external">protein C concentrate</a> was associated with resolution of coagulopathy with no adverse effects; there was no significant difference in amputation rate or mortality [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an open-label study of protein C replacement in 36 patients (mean age 12 years) with purpura fulminans, survival was improved and there were fewer amputations than predicted from historical controls [<a href="#rid52">52</a>]. However, because of the limited data supporting the use of <a class="drug drug_general" data-topicid="10094" href="/d/drug information/10094.html" rel="external">protein C concentrate</a>, it has not been used commonly in the therapy of meningococcal infections.</p><p></p><p class="headingAnchor" id="H4105978585"><span class="h3">Supportive care</span><span class="headingEndMark"> — </span>Since the occurrence of shock is frequent in patients with meningococcal infection, therapy should be provided in a tertiary care medical facility whenever possible. If patients with meningococcal sepsis arrive at hospitals without such capabilities, they should be treated with appropriate antimicrobial therapy and promptly transferred to a facility with a fully staffed intensive care unit. Vasopressor and aggressive fluid replacement are integral components in the management of septic shock. (See  <a class="medical medical_review" href="/d/html/6397.html" rel="external">"Shock in children in resource-abundant settings: Initial management"</a> and  <a class="medical medical_review" href="/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Treatment of complications</span></p><p class="headingAnchor" id="H155902323"><span class="h3">Disseminated intravascular coagulation and purpura fulminans</span><span class="headingEndMark"> — </span>Purpura fulminans is a thrombotic disorder characterized by extravasation of blood into the tissues producing ecchymoses and petechiae and is often accompanied by disseminated intravascular coagulation (DIC). While petechiae are common in meningococcal infection, increasing numbers of petechiae, confluent ecchymoses, persistently bleeding venipuncture sites, and bleeding gums despite adequate antimicrobial therapy and supportive care are suggestive of DIC. (See  <a class="medical medical_review" href="/d/html/1300.html" rel="external">"Clinical manifestations of meningococcal infection"</a>.)</p><p>Early and aggressive interventions with antimicrobials and support of vascular perfusion are keys to prevention of DIC and purpura fulminans. Once purpura fulminans has developed, surgical debridement of lesions and skin grafting may be necessary in some cases. Deep necrosis of limbs or digits may necessitate amputation [<a href="#rid53">53</a>]. Other possible therapies of DIC and purpura fulminans are discussed separately. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Other life-threatening complications</span><span class="headingEndMark"> — </span>Other major life-threatening complications necessitating therapy include acute respiratory distress syndrome (ARDS), neurologic sequelae ranging from coma to diabetes insipidus, nosocomial pneumonia due to superinfection or aspiration during the obtunded state, and pericarditis. (See  <a class="medical medical_review" href="/d/html/1641.html" rel="external">"Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults"</a>.)</p><p>Primary purulent meningococcal pericarditis can be particularly insidious, presenting as a massive pericardial effusion and tamponade. Pericardiocentesis is often indicated for improved hemodynamic function. (See  <a class="medical medical_review" href="/d/html/1300.html" rel="external">"Clinical manifestations of meningococcal infection", section on 'Pericarditis'</a> and  <a class="medical medical_review" href="/d/html/2128.html" rel="external">"Purulent pericarditis"</a>.)</p><p>By contrast, sterile pericarditis, a post-infectious immune complex complication, can appear as a manifestation during convalescence and responds to anti-inflammatory drugs.</p><p class="headingAnchor" id="H18"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>Before antibiotics and immune serum were available, the mortality of meningococcal infection was 70 to 90 percent [<a href="#rid54">54</a>]. The prognosis of meningococcal disease was dramatically improved by the introduction of sulfonamides in the late 1930s, followed by penicillin a decade later. The mortality rates in the United States, as reported by the Centers for Disease Control and Prevention (CDC), are 10 to 15 percent [<a href="#rid55">55</a>]. This mortality rate is similar to that in the late 1960s despite major advancements in supportive care [<a href="#rid56">56-58</a>].</p><p>Several studies have attempted to establish prognostic criteria for the outcome of meningococcal sepsis [<a href="#rid4">4,59</a>]. In a Spanish study, the major significant independent predictors of death were a hemorrhagic diathesis, focal neurologic signs, and age ≥60 years (odds ratio [OR] 101, 25, and 10, respectively) [<a href="#rid4">4</a>]. Early antibiotic therapy was associated with good outcomes. (See <a class="local">'Importance of early administration'</a> above.)</p><p>An increased case-fatality rate is associated with outbreaks compared with sporadic meningococcal disease. The magnitude of this difference was illustrated in a retrospective analysis of cases in the United States from 1994 to 2002 [<a href="#rid60">60</a>]. Active surveillance identified 668 cases, of which 229 patients (69 clusters) met the criteria of either a community-based or organizational outbreak. After controlling for age, serogroup, and clinical presentation, outbreak-associated cases were associated with a significantly higher case-fatality rate than were sporadic cases (21 versus 11 percent; OR 3.3; 95% CI 2.0-5.5).</p><p>The presence of hypervirulent meningococcal strains (clonal complex 11) has also been associated with an increased incidence of sepsis and poor outcomes. This clonal complex is found among most serotypes but occurs most frequently among serogroup C strains [<a href="#rid61">61,62</a>].</p><p>Sex may influence prognosis. In one study from New York including 151 cases of invasive meningococcal disease between 2008 and 2016, a higher case-fatality rate was observed among women (adjusted relative risk [RR] 2.1, 95% CI 1.2-3.8); among patients with meningitis, the RR was 13.7 (95% CI 3.2-58.1) [<a href="#rid63">63</a>]. The basis for these differences is not understood.</p><p class="headingAnchor" id="H19"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span><em>N. meningitidis</em> is spread by large respiratory droplets or direct contact with respiratory secretions. The methods for the prevention of meningococcal infection include antimicrobial chemoprophylaxis following identification of an index case, use of droplet precautions, vaccination prior to exposure, and avoidance of exposure [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/1298.html" rel="external">"Epidemiology of Neisseria meningitidis infection", section on 'Risk factors for acquisition of infection'</a>.)</p><p class="headingAnchor" id="H365639476"><span class="h2">Droplet precautions</span><span class="headingEndMark"> — </span>Droplet precautions should be continued for 24 hours after institution of effective antibiotics in patients with suspected or confirmed <em>N. meningitidis</em> infection [<a href="#rid2">2</a>]. After 24 hours, viable organisms can no longer be isolated from treated patients. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Droplet precautions'</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Antimicrobial chemoprophylaxis</span></p><p class="headingAnchor" id="H3977927766"><span class="h3">Following exposure</span><span class="headingEndMark"> — </span>Antimicrobial chemoprophylaxis was first used successfully to abort the spread of meningococcal infection in the 1930s [<a href="#rid64">64</a>]. The reported attack rate for close contacts of patients with sporadic meningococcal disease is approximately 4 in 1000 persons exposed (0.4 percent), which is 500 to 800 times higher than that of the general population [<a href="#rid65">65,66</a>].</p><p class="headingAnchor" id="H199038116"><span class="h4">Indications</span><span class="headingEndMark"> — </span>Chemoprophylaxis is indicated in close contacts of patients with meningococcal infection and should be given as early as possible following the exposure [<a href="#rid66">66,67</a>]. Although "close contact" has not been clearly defined, it generally refers to individuals who have had prolonged (&gt;8 hours) contact while in close proximity (&lt;3 feet) to the patient or who have been directly exposed to the patient's oral secretions during the seven days before the onset of the patient's symptoms and until 24 hours after initiation of appropriate antibiotic therapy [<a href="#rid2">2</a>].</p><p>Close contacts may include individuals exposed in the following ways [<a href="#rid2">2,66</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Household members, roommates, intimate contacts, contacts at a childcare center, young adults exposed in dormitories, military recruits exposed in training centers</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Travelers who had direct contact with respiratory secretions from an index patient or who were seated directly next to an index patient on a prolonged flight (ie, one lasting ≥8 hours)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals who have been exposed to oral secretions (eg, intimate kissing, mouth-to-mouth resuscitation, endotracheal intubation, or endotracheal tube management)</p><p></p><p>Prophylaxis is <strong>not</strong> indicated if exposure to the index case is brief. This includes the majority of health care workers unless there is direct exposure to respiratory secretions (as with suctioning or intubation). The attack rate in health care workers at risk is increased compared with that of the general population, but the absolute increase in risk is very small, and antimicrobial prophylaxis is therefore not recommended for health care workers who have not had direct exposure to respiratory secretions [<a href="#rid66">66,68</a>].</p><p>Oropharyngeal or nasopharyngeal cultures are not helpful in determining the need for chemoprophylaxis and might unnecessarily delay institution of this preventive measure [<a href="#rid66">66</a>].</p><p>Evidence supporting chemoprophylaxis is limited, but we favor it because of the potential severity of meningococcal infection in individuals with high-risk exposure. Evidence informing chemoprophylaxis is discussed elsewhere. (See <a class="local">'Regimens'</a> below.)</p><p class="headingAnchor" id="H199038123"><span class="h4">Timing of prophylaxis</span><span class="headingEndMark"> — </span>Antimicrobial chemoprophylaxis should be administered as early as possible (ideally &lt;24 hours after identification of the index patient). Chemoprophylaxis administered &gt;14 days after exposure to the index case is probably of limited or no value and is therefore <strong>not</strong> recommended by the United States Centers for Disease Control and Prevention (CDC) [<a href="#rid66">66</a>].</p><p>The rate of secondary disease in contacts is highest immediately after the onset of disease in the index patient. Secondary cases usually occur within 10 days of the primary case, but longer intervals have been described in rare case reports [<a href="#rid69">69</a>].</p><p>In the setting of a suspected meningococcal disease outbreak in which confirmed cases have occurred, it is not necessary to wait for confirmation of <em>N. meningitidis</em> in subsequent cases to initiate chemoprophylaxis of close contacts when meningococcal disease is strongly suspected (eg, identification of gram-negative diplococci, detection of <em>N. meningitidis</em> antigen from cerebrospinal fluid [CSF] by latex or from formalin-fixed tissue by immunohistochemistry, or when there are clinical signs such as purpura) [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H199038180"><span class="h4">Regimens</span><span class="headingEndMark"> — </span>To help inform regimen selection for chemoprophylaxis, clinicians should consult with local public health authorities. In the United States, information can also be found on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmeningococcal%2Fclinical-info.html%23prevention&amp;token=PJxpeY07Y39e0dIdDRynoFLWLN1kkz5SM3HtXGySDl0UgsJAWY2nj6kmPKjNUg0ng%2F2YSKajb3Mp9T502W7AZfh8zmfYA%2FB8uLAX%2FdIMPRM%3D&amp;TOPIC_ID=1274" target="_blank">CDC website</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred regimens</strong> – Preferred regimens for antimicrobial prophylaxis include <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, and <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>  (<a class="graphic graphic_table graphicRef51944" href="/d/graphic/51944.html" rel="external">table 1</a>) [<a href="#rid66">66,70</a>]. The choice of agent depends in part upon antimicrobial susceptibility within a community. As an example, ciprofloxacin should not be used for chemoprophylaxis of close contacts of individuals with meningococcal disease when ciprofloxacin-resistant <em>N. meningitidis</em> has been identified in the local community [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1">Quinolone resistance has been increasingly reported and has been detected worldwide. Ciprofloxacin-resistant <em>N. meningitidis</em> isolates were detected in three patients in North Dakota and Minnesota in 2007 [<a href="#rid71">71,72</a>]. In 2008, a case of pneumonia caused by ciprofloxacin-resistant <em>N. meningitidis</em> was detected in California as part of the United States Active Bacterial Core surveillance system [<a href="#rid72">72</a>]. From 2019 to 2020, 11 ciprofloxacin-resistant, beta-lactamase-producing isolates of <em>N. meningitidis</em> were detected in eight states [<a href="#rid15">15</a>]. Isolated ciprofloxacin-resistant isolates have also been reported from a variety of other countries around the world [<a href="#rid71">71,73,74</a>]. In Spain, 10 of 5300 isolates of <em>N. meningitidis</em> that were collected between 1999 and 2006 had reduced susceptibility to <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative regimens</strong> – <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> is an alternative agent for prophylaxis if one of the preferred agents cannot be used (eg, if <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> or <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> are contraindicated in the setting of a ciprofloxacin-resistant <em>N. meningitidis </em>exposure). In adults, the dose of azithromycin is 500 mg orally as a single dose; in children, the dose is 10 mg/kg orally as a single dose (max dose 500 mg). Although azithromycin has significant activity against meningococcus, it is not recommended as a first-line agent for chemoprophylaxis since it has not been well studied for this indication.</p><p></p><p class="bulletIndent1">Evidence informing the clinical effectiveness of antimicrobial prophylaxis in preventing disease is limited. The potential clinical benefit of prophylaxis is inferred from studies that demonstrate eradication of nasopharyngeal carriage with antimicrobials.</p><p></p><p>Specifically, a 2013 meta-analysis of 24 randomized or quasi-randomized clinical trials evaluated the effectiveness of antibiotic treatments for eradication of nasopharyngeal carriage at one to two weeks after treatment [<a href="#rid75">75</a>]. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> (RR 0.20, 95% CI 0.14-0.29) and <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (RR 0.03, 95% CI 0.00-0.42) were significantly effective at eradicating <em>N. meningitidis</em> carriage compared with placebo at one to two weeks. Rifampin continued to be effective for up to four weeks after therapy, but resistant isolates were seen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Based on the results of a single study, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> was more effective than <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (RR 5.93, 95% CI 1.22-28.68) at eradicating <em>N. meningitidis</em> carriage after one to two weeks of follow-up. No trials have evaluated ceftriaxone against placebo, and the drug must be administered parenterally.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical efficacy of eradication could not be assessed since there were no cases of disease following antibiotics or placebo.</p><p></p><p class="headingAnchor" id="H2543158685"><span class="h4">Follow-up of close contacts</span><span class="headingEndMark"> — </span>Surveillance of close contacts receiving prophylaxis for at least 10 days following exposure as well as counseling about the signs and symptoms of meningococcal infection ensure prompt treatment of any secondary cases that might arise.</p><p class="headingAnchor" id="H2536994243"><span class="h3">Patients receiving C5 inhibitors</span><span class="headingEndMark"> — </span>We suggest patients treated with C5 inhibitors (eg, <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> and <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a>) receive antimicrobial prophylaxis for the duration of C5 inhibitor administration, in addition to meningococcal vaccination. It is also important to keep their vaccines up to date. (See  <a class="medical medical_review" href="/d/html/3901.html" rel="external">"Meningococcal vaccination in children and adults", section on 'Immunization of persons at increased risk'</a>.)</p><p>Antimicrobial prophylaxis for prevention of meningococcal infection in the setting of C5 inhibitor use consists of <a class="drug drug_general" data-topicid="9751" href="/d/drug information/9751.html" rel="external">penicillin V</a> (for adults 500 mg orally twice daily; for children ≥3 years of age 250 mg orally twice daily; for children &lt;3 years of age 125 mg orally twice daily). In the presence of penicillin allergy, a macrolide such as <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (in adults 500 mg orally once daily; in children 5 mg/kg orally once daily [maximum dose 500 mg]) can be substituted, based on the relatively narrow spectrum and efficacy against the meningococcus.</p><p>Since neither vaccination nor antimicrobial prophylaxis can be expected to prevent all cases of meningococcal disease, patients on C5 inhibitors should be educated about the risk of infection and encouraged to seek medical care immediately if any symptoms (fever, headache, altered mentation, rash) of meningococcal disease occur. (See  <a class="medical medical_review" href="/d/html/1300.html" rel="external">"Clinical manifestations of meningococcal infection"</a>.)</p><p>C5 inhibitors are monoclonal antibody terminal complement inhibitors used for treatment of complement-mediated hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, myasthenia gravis, and other autoimmune diseases. Administration of C5 inhibitors has been associated with a 1000- to 2000-fold increased risk of meningococcal infection [<a href="#rid76">76</a>], and life-threatening and fatal meningococcal infections have been reported [<a href="#rid77">77</a>].</p><p>Invasive meningococcal disease has occurred in patients receiving C5 inhibitors despite receipt of meningococcal vaccines (both MenA/C/W/Y protein-polysaccharide vaccines and MenB-directed vaccines), including infections caused by nontypeable strains not included as the targets of these vaccines [<a href="#rid76">76,78</a>]. This is due to inhibition of both complement-mediated bactericidal activity and also complement-mediated opsonic functions by C5 inhibitors.</p><p>Although there is a lack of clear evidence supporting the use of prophylactic antibiotics, there is a trend toward prolonged time to onset among prophylaxis users [<a href="#rid79">79,80</a>]. However, there is also a trend towards increased penicillin nonsusceptibility if infection occurs, which may impact regimen selection. (See <a class="local">'Therapy based on results of susceptibility testing'</a> above.)</p><p class="headingAnchor" id="H22"><span class="h2">Vaccination</span><span class="headingEndMark"> — </span>Meningococcal vaccines and the indications for immunization are discussed separately. (See  <a class="medical medical_review" href="/d/html/3901.html" rel="external">"Meningococcal vaccination in children and adults"</a> and  <a class="medical medical_patient" href="/d/html/4003.html" rel="external">"Patient education: Vaccines for adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1216.html" rel="external">"Patient education: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1218.html" rel="external">"Patient education: Vaccines for children age 7 to 18 years (Beyond the Basics)"</a>.)</p><p class="headingAnchor" id="H3838402053"><span class="h1">MANAGEMENT OF N. MENINGITIDIS FROM OTHER SITES</span></p><p class="headingAnchor" id="H840125981"><span class="h2">Urethritis</span><span class="headingEndMark"> — </span>Meningococcal urethritis is indistinguishable from acute gonococcal urethritis (a more common cause of genitourinary infection) based on clinical features and Gram stain [<a href="#rid81">81,82</a>]. However, the gonorrhea nucleic acid amplification testing (NAAT) is negative in meningococcal urethritis. Both pathogens are susceptible to similar antibacterial agents (eg, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>), so the treatment of presumed gonorrhea infections will typically be effective for patients with meningococcal infections of the genitourinary tract (including urethritis, epididymitis, and pelvic inflammatory disease). (See  <a class="medical medical_review" href="/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents"</a> and  <a class="medical medical_review" href="/d/html/7585.html" rel="external">"Pelvic inflammatory disease: Treatment in adults and adolescents"</a>.)</p><p class="headingAnchor" id="H1816071429"><span class="h2">Other rare sites of infection</span><span class="headingEndMark"> — </span>Antimicrobial regimens used for treatment of other rare sites of infection (eg, arthritis, pericarditis, pneumonia) include <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (2 g every 24 hours for adults or 50 mg/kg [maximum 2 g] every 12 to 24 hours for children) or high-dose <a class="drug drug_general" data-topicid="9749" href="/d/drug information/9749.html" rel="external">penicillin G</a> (for adults 4 million units intravenous [IV] every four hours; for children 300,000 units/kg per day in a divided dose every six hours [usual maximum dose 12 million units/day]). There are limited data to guide the duration of treatment; regimens are typically administered for five to seven days but may be extended up to two weeks in patients with pericarditis.</p><p>In addition to antimicrobial therapy, some infections (such as arthritis and pericarditis) warrant drainage of fluid from the site of infection.</p><p class="headingAnchor" id="H1602912073"><span class="h2">Incidental nasopharyngeal isolation</span><span class="headingEndMark"> — </span>Occasionally, <em>N. meningitidis</em> is detected on throat or nasopharyngeal culture obtained for some other reason. The most common indication is pharyngitis, which is not caused by <em>N. meningitidis</em>. Although nasopharyngeal carriage with <em>N. meningitidis</em> plays an important role in the transmission and the development of invasive disease, there is no role for treatment of patients with detection of <em>N. meningitidis</em> on throat or nasopharyngeal culture in the absence of invasive disease or exposure to a case or in an ongoing outbreak. (See  <a class="medical medical_review" href="/d/html/1276.html" rel="external">"Microbiology and pathobiology of Neisseria meningitidis", section on 'Nasopharyngeal carriage'</a>.)</p><p>There are several problems with attempting to eliminate nasopharyngeal carriage in the community:</p><p class="bulletIndent1"><span class="glyph">●</span>Spontaneous loss and acquisition of <em>N. meningitidis</em> carriage is common. This was illustrated in a study in military recruits in which 34 percent experienced one or more changes in carrier status over time [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent colonization may occur after prophylaxis. In a community-wide prophylaxis program in a semi-closed kibbutz population in Israel, the colonization rate of serogroup B meningococcus dropped from 4.6 percent at baseline to 0 percent at three weeks; it then rose to 0.5 percent at six months and 3.9 percent (similar to the baseline level) at one year [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antimicrobial prophylaxis has no proven clinical efficacy outside an outbreak setting. The meta-analysis cited above included trials in healthy carriers [<a href="#rid75">75</a>]. Clinical efficacy of eradication could not be assessed since there were no cases of disease following antibiotics or placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibiotic resistance. <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> treatment can result in the rapid emergence of rifampin-resistant meningococci in the patients treated [<a href="#rid85">85</a>].</p><p></p><p class="headingAnchor" id="H2085956815"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104441.html" rel="external">"Society guideline links: Bacterial meningitis in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/109396.html" rel="external">"Society guideline links: Meningococcal infection"</a> and  <a class="medical medical_society_guidelines" href="/d/html/110423.html" rel="external">"Society guideline links: Bacterial meningitis in infants and children"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimicrobial therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy</strong> – Empiric coverage for meningococcal infection is warranted in patients with suspected invasive meningococcal infection (severe sepsis syndrome, fever with petechiae and/or ecchymoses, or suspected bacterial meningitis). (See  <a class="medical medical_review" href="/d/html/1290.html" rel="external">"Initial therapy and prognosis of community-acquired bacterial meningitis in adults"</a>.)</p><p></p><p class="bulletIndent2">Prompt administration of effective antibiotics early in the disease is key to a successful outcome of life-threatening meningococcal infection. (See <a class="local">'Importance of early administration'</a> above.)</p><p></p><p class="bulletIndent2">For initial therapy of patients with suspected meningococcal meningitis or sepsis, we recommend <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> rather than intravenous (IV) <a class="drug drug_general" data-topicid="9749" href="/d/drug information/9749.html" rel="external">penicillin G</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). The dose of ceftriaxone is 2 g IV every 12 hours for adults or 50 mg/kg (maximum 2 g) IV every 12 hours for children. Third-generation cephalosporins, such as ceftriaxone, have very low rates of resistance, are easy to dose, and are also effective for eradication of nasopharyngeal carriage of meningococcus. (See <a class="local">'Therapy pending results of susceptibility testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Therapy based on susceptibility testing</strong> – If susceptibility testing indicates that the isolate is penicillin susceptible (minimum inhibitory concentration [MIC] &lt;0.1 mcg/mL), either <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> or high-dose <a class="drug drug_general" data-topicid="9749" href="/d/drug information/9749.html" rel="external">penicillin G</a> (for adults 4 million units IV every four hours; for children 300,000 units/kg per day in a divided dose every six hours [usual maximum dose 12 million units/day]) can be used. (See <a class="local">'Therapy based on results of susceptibility testing'</a> above.)</p><p></p><p class="bulletIndent2">Most isolates that have reduced susceptibility to penicillin (MIC ≥0.1 mcg/mL) are susceptible to <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients intolerant to beta-lactams</strong> – For patients who are intolerant to beta-lactams, the approach to treatment depends upon the nature of the allergy. For those who cannot use beta-lactams, <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> (100 mg/kg per day IV in divided doses every six hours, up to a maximum dose of 4 g/day) is an effective substitute in areas where it is available. <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">Meropenem</a>, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a>, <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>, and possibly <a class="drug drug_general" data-topicid="9047" href="/d/drug information/9047.html" rel="external">aztreonam</a> are also alternatives, although clinical experience and data on their use remain limited and increasing resistance to fluoroquinolones a concern. (See <a class="local">'Patients intolerant of beta-lactams'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Eradication of nasal carriage</strong> – If an antibiotic other than <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> is used for treatment, we suggest adding a second agent for eradication of presumed nasopharyngeal carriage to prevent subsequent transmission to close contacts (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Options for a second agent are the same as those used for chemoprophylaxis  (<a class="graphic graphic_table graphicRef51944" href="/d/graphic/51944.html" rel="external">table 1</a>). (See <a class="local">'Eradication of nasal carriage for select patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of shock</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of </strong><a class="drug drug_general" data-topicid="10094" href="/d/drug information/10094.html" rel="external">protein C concentrate</a> – For patients with severe meningococcal sepsis, including those with purpura fulminans, we suggest protein C concentrate in addition to supportive care (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Patients with severe meningococcal sepsis have impaired activation of protein C, which contributes to coagulopathic complications. (See <a class="local">'Protein C concentrate'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infection control precautions</strong> – Droplet precautions should be used for patients with suspected or confirmed <em>Neisseria meningitidis</em> infection. These should be continued for 24 hours after institution of effective antibiotics. (See <a class="local">'Droplet precautions'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of close contact</strong> – For close contacts of patients with meningococcal meningitis or sepsis, we suggest antimicrobial chemoprophylaxis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Antimicrobial chemoprophylaxis should be administered as early as possible (ideally &lt;24 hours after identification of the index patient and not &gt;14 days after exposure). (See <a class="local">'Indications'</a> above and <a class="local">'Timing of prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2">Regimens for antimicrobial prophylaxis include <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, and <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>  (<a class="graphic graphic_table graphicRef51944" href="/d/graphic/51944.html" rel="external">table 1</a>). (See <a class="local">'Regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Persons receiving C5 inhibitors</strong> – In patients receiving C5 inhibitors, we suggest administration of daily antimicrobial prophylaxis with oral <a class="drug drug_general" data-topicid="9751" href="/d/drug information/9751.html" rel="external">penicillin V</a> for the duration of C5 inhibitor administration (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Administration of C5 inhibitors has been associated with increased incidence of meningococcal disease. Antimicrobial prophylaxis should be used in addition to meningococcal vaccination. (See <a class="local">'Patients receiving C5 inhibitors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vaccination</strong> – Meningococcal vaccines are discussed separately. (See  <a class="medical medical_review" href="/d/html/3901.html" rel="external">"Meningococcal vaccination in children and adults"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001; 344:1378.</a></li><li><a class="nounderline abstract_t">Gardner P. Clinical practice. Prevention of meningococcal disease. N Engl J Med 2006; 355:1466.</a></li><li><a class="nounderline abstract_t">Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369:2196.</a></li><li><a class="nounderline abstract_t">Barquet N, Domingo P, Caylà JA, et al. Prognostic factors in meningococcal disease. Development of a bedside predictive model and scoring system. Barcelona Meningococcal Disease Surveillance Group. JAMA 1997; 278:491.</a></li><li><a class="nounderline abstract_t">Cartwright K, Reilly S, White D, Stuart J. Early treatment with parenteral penicillin in meningococcal disease. BMJ 1992; 305:143.</a></li><li><a class="nounderline abstract_t">Strang JR, Pugh EJ. Meningococcal infections: reducing the case fatality rate by giving penicillin before admission to hospital. BMJ 1992; 305:141.</a></li><li><a class="nounderline abstract_t">Riordan FA. Improving promptness of antibiotic treatment in meningococcal disease. Emerg Med J 2001; 18:162.</a></li><li><a class="nounderline abstract_t">Hart CA, Thomson AP. Meningococcal disease and its management in children. BMJ 2006; 333:685.</a></li><li><a class="nounderline abstract_t">Lala HM, Mills GD, Barratt K, et al. Meningococcal disease deaths and the frequency of antibiotic administration delays. J Infect 2007; 54:551.</a></li><li><a class="nounderline abstract_t">Darton T, Guiver M, Naylor S, et al. Severity of meningococcal disease associated with genomic bacterial load. Clin Infect Dis 2009; 48:587.</a></li><li><a class="nounderline abstract_t">Crosswell JM, Nicholson WR, Lennon DR. Rapid sterilisation of cerebrospinal fluid in meningococcal meningitis: Implications for treatment duration. J Paediatr Child Health 2006; 42:170.</a></li><li><a class="nounderline abstract_t">Chaudhuri A, Martinez-Martin P, Kennedy PG, et al. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults. Eur J Neurol 2008; 15:649.</a></li><li><a class="nounderline abstract_t">McGill F, Heyderman RS, Michael BD, et al. Corrigendum to "The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent Adults" [J Infect 72 (2016) 405-438]. J Infect 2016; 72:768.</a></li><li><a class="nounderline abstract_t">Cabellos C, Pelegrín I, Benavent E, et al. Impact of pre-hospital antibiotic therapy on mortality in invasive meningococcal disease: a propensity score study. Eur J Clin Microbiol Infect Dis 2019; 38:1671.</a></li><li><a class="nounderline abstract_t">McNamara LA, Potts C, Blain AE, et al. Detection of Ciprofloxacin-Resistant, β-Lactamase-Producing Neisseria meningitidis Serogroup Y Isolates - United States, 2019-2020. MMWR Morb Mortal Wkly Rep 2020; 69:735.</a></li><li><a class="nounderline abstract_t">Willerton L, Lucidarme J, Walker A, et al. Antibiotic resistance among invasive Neisseria meningitidis isolates in England, Wales and Northern Ireland (2010/11 to 2018/19). PLoS One 2021; 16:e0260677.</a></li><li><a class="nounderline abstract_t">Asturias EJ, Bai X, Bettinger JA, et al. Meningococcal disease in North America: Updates from the Global Meningococcal Initiative. J Infect 2022; 85:611.</a></li><li><a class="nounderline abstract_t">Potts CC, Rodriguez-Rivera LD, Retchless AC, et al. Antimicrobial Susceptibility Survey of Invasive Neisseria meningitidis, United States 2012-2016. J Infect Dis 2022; 225:1871.</a></li><li><a class="nounderline abstract_t">Deghmane AE, Hong E, Taha MK. Emergence of meningococci with reduced susceptibility to third-generation cephalosporins. J Antimicrob Chemother 2017; 72:95.</a></li><li><a class="nounderline abstract_t">Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.</a></li><li><a class="nounderline abstract_t">Grubbauer HM, Dornbusch HJ, Dittrich P, et al. Ceftriaxone monotherapy for bacterial meningitis in children. Chemotherapy 1990; 36:441.</a></li><li><a class="nounderline abstract_t">Marhoum el Filali K, Noun M, Chakib A, et al. Ceftriaxone versus penicillin G in the short-term treatment of meningococcal meningitis in adults. Eur J Clin Microbiol Infect Dis 1993; 12:766.</a></li><li class="breakAll">American Academy of Pediatrics. Meningococcal infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds) (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.519.</li><li><a class="nounderline abstract_t">Nau R, Prange HW, Muth P, et al. Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. Antimicrob Agents Chemother 1993; 37:1518.</a></li><li><a class="nounderline abstract_t">Barson WJ, Miller MA, Brady MT, Powell DA. Prospective comparative trial of ceftriaxone vs. conventional therapy for treatment of bacterial meningitis in children. Pediatr Infect Dis 1985; 4:362.</a></li><li><a class="nounderline abstract_t">Cabellos C, Pelegrín I, Benavent E, et al. Invasive meningococcal disease: Impact of short course therapy. A DOOR/RADAR study. J Infect 2017; 75:420.</a></li><li><a class="nounderline abstract_t">Lentnek AL, Williams RR. Aztreonam in the treatment of gram-negative bacterial meningitis. Rev Infect Dis 1991; 13 Suppl 7:S586.</a></li><li><a class="nounderline abstract_t">Sáez-Nieto JA, Lujan R, Berrón S, et al. Epidemiology and molecular basis of penicillin-resistant Neisseria meningitidis in Spain: a 5-year history (1985-1989). Clin Infect Dis 1992; 14:394.</a></li><li><a class="nounderline abstract_t">Sprott MS, Kearns AM, Field JM. Penicillin-insensitive Neisseria meningitidis. Lancet 1988; 1:1167.</a></li><li><a class="nounderline abstract_t">Mendelman PM, Campos J, Chaffin DO, et al. Relative penicillin G resistance in Neisseria meningitidis and reduced affinity of penicillin-binding protein 3. Antimicrob Agents Chemother 1988; 32:706.</a></li><li><a class="nounderline abstract_t">Sameed M, Nwaiser C, Bhandari P, Schmalzle SA. Meropenem-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with known type IV penicillin hypersensitivity. BMJ Case Rep 2019; 12.</a></li><li><a class="nounderline abstract_t">Klugman KP, Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. Antimicrob Agents Chemother 1995; 39:1140.</a></li><li><a class="nounderline abstract_t">Wong VK, Wright HT Jr, Ross LA, et al. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991; 10:122.</a></li><li><a class="nounderline abstract_t">Galimand M, Gerbaud G, Guibourdenche M, et al. High-level chloramphenicol resistance in Neisseria meningitidis. N Engl J Med 1998; 339:868.</a></li><li><a class="nounderline abstract_t">Scotton PG, Pea F, Giobbia M, et al. Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis. Clin Infect Dis 2001; 33:e109.</a></li><li><a class="nounderline abstract_t">Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging 2010; 27:193.</a></li><li><a class="nounderline abstract_t">Lin TY, Chrane DF, Nelson JD, McCracken GH Jr. Seven days of ceftriaxone therapy is as effective as ten days' treatment for bacterial meningitis. JAMA 1985; 253:3559.</a></li><li><a class="nounderline abstract_t">Abramson JS, Spika JS. Persistence of Neisseria meningitidis in the upper respiratory tract after intravenous antibiotic therapy for systemic meningococcal disease. J Infect Dis 1985; 151:370.</a></li><li><a class="nounderline abstract_t">Artenstein MS, Lamson TH, Evans JR. Attempted prophylaxis against meningococcal infection using intramuscular penicillin. Mil Med 1967; 132:1009.</a></li><li><a class="nounderline abstract_t">Hoeprich PD. Prediction of antimeningococcic chemoprophylactic efficacy. J Infect Dis 1971; 123:125.</a></li><li><a class="nounderline abstract_t">Nathan N, Borel T, Djibo A, et al. Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study. Lancet 2005; 366:308.</a></li><li><a class="nounderline abstract_t">Chippaux JP, Soula G, Campagne G, Rey M. [Optimizing the response to epidemics of meningococcal meningitis: report of a workshop of experts at CERMES (Niamey, Niger, 12th to 14th January 1998)]. Sante 1998; 8:245.</a></li><li><a class="nounderline abstract_t">Ellis-Pegler R, Galler L, Roberts S, et al. Three days of intravenous benzyl penicillin treatment of meningococcal disease in adults. Clin Infect Dis 2003; 37:658.</a></li><li><a class="nounderline abstract_t">de Gans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347:1549.</a></li><li><a class="nounderline abstract_t">Belsey MA, Hoffpauir CW, Smith MH. Dexamethasone in the treatment of acute bacterial meningitis: the effect of study design on the interpretation of results. Pediatrics 1969; 44:503.</a></li><li><a class="nounderline abstract_t">Brouwer MC, McIntyre P, de Gans J, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2010; :CD004405.</a></li><li><a class="nounderline abstract_t">van de Beek D, Brouwer MC, Koedel U, Wall EC. Community-acquired bacterial meningitis. Lancet 2021; 398:1171.</a></li><li><a class="nounderline abstract_t">Tolaj I, Ramadani H, Mehmeti M, et al. Does Dexamethasone Helps in Meningococcal Sepsis? Med Arch 2017; 71:173.</a></li><li><a class="nounderline abstract_t">Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345:408.</a></li><li><a class="nounderline abstract_t">Alberio L, Lämmle B, Esmon CT. Protein C replacement in severe meningococcemia: rationale and clinical experience. Clin Infect Dis 2001; 32:1338.</a></li><li><a class="nounderline abstract_t">de Kleijn ED, de Groot R, Hack CE, et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 2003; 31:1839.</a></li><li><a class="nounderline abstract_t">White B, Livingstone W, Murphy C, et al. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000; 96:3719.</a></li><li><a class="nounderline abstract_t">Wheeler JS, Anderson BJ, De Chalain TM. Surgical interventions in children with meningococcal purpura fulminans--a review of 117 procedures in 21 children. J Pediatr Surg 2003; 38:597.</a></li><li><a class="nounderline abstract_t">Flexner S. THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS. J Exp Med 1913; 17:553.</a></li><li><a class="nounderline abstract_t">Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020; 69:1.</a></li><li><a class="nounderline abstract_t">Goldacre MJ, Roberts SE, Yeates D. Case fatality rates for meningococcal disease in an English population, 1963-98: database study. BMJ 2003; 327:596.</a></li><li><a class="nounderline abstract_t">Andersen BM. Mortality in meningococcal infections. Scand J Infect Dis 1978; 10:277.</a></li><li><a class="nounderline abstract_t">Wolf RE, Birbara CA. Meningococcal infections at an army training center. Am J Med 1968; 44:243.</a></li><li><a class="nounderline abstract_t">Kornelisse RF, Hazelzet JA, Hop WC, et al. Meningococcal septic shock in children: clinical and laboratory features, outcome, and development of a prognostic score. Clin Infect Dis 1997; 25:640.</a></li><li><a class="nounderline abstract_t">Brooks R, Woods CW, Benjamin DK Jr, Rosenstein NE. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis 2006; 43:49.</a></li><li><a class="nounderline abstract_t">Stefanelli P, Fazio C, Neri A, et al. Genome-based study of a spatio-temporal cluster of invasive meningococcal disease due to Neisseria meningitidis serogroup C, clonal complex 11. J Infect 2016; 73:136.</a></li><li><a class="nounderline abstract_t">Heckenberg SG, de Gans J, Brouwer MC, et al. Clinical features, outcome, and meningococcal genotype in 258 adults with meningococcal meningitis: a prospective cohort study. Medicine (Baltimore) 2008; 87:185.</a></li><li><a class="nounderline abstract_t">Bloch D, Murray K, Peterson E, et al. Sex Difference in Meningococcal Disease Mortality, New York City, 2008-2016. Clin Infect Dis 2018; 67:760.</a></li><li><a class="nounderline abstract_t">Schwentker FF, Gelman S, Long PH. Landmark article April 24, 1937. The treatment of meningococcic meningitis with sulfanilamide. Preliminary report. By Francis F. Schwentker, Sidney Gelman, and Perrin H. Long. JAMA 1984; 251:788.</a></li><li><a class="nounderline abstract_t">Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis. J Infect Dis 1976; 134:201.</a></li><li><a class="nounderline abstract_t">Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Guidance for the Evaluation and Public Health Management of Suspected Outbreaks of Meningococcal Disease version 2.0. September 2019. https://www.cdc.gov/meningococcal/downloads/meningococcal-outbreak-guidance.pdf (Accessed on October 21, 2020).</li><li><a class="nounderline abstract_t">Gilmore A, Stuart J, Andrews N. Risk of secondary meningococcal disease in health-care workers. Lancet 2000; 356:1654.</a></li><li><a class="nounderline abstract_t">Neal KR, Nguyen-van-Tam JS, Slack RC, et al. Seven-week interval between acquisition of a meningococcus and the onset of invasive disease. A case report. Epidemiol Infect 1999; 123:507.</a></li><li><a class="nounderline abstract_t">Schwartz B, Al-Tobaiqi A, Al-Ruwais A, et al. Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of group A Neisseria meningitidis. Lancet 1988; 1:1239.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Emergence of fluoroquinolone-resistant Neisseria meningitidis--Minnesota and North Dakota, 2007-2008. MMWR Morb Mortal Wkly Rep 2008; 57:173.</a></li><li><a class="nounderline abstract_t">Wu HM, Harcourt BH, Hatcher CP, et al. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med 2009; 360:886.</a></li><li><a class="nounderline abstract_t">Enríquez R, Abad R, Salcedo C, et al. Fluoroquinolone resistance in Neisseria meningitidis in Spain. J Antimicrob Chemother 2008; 61:286.</a></li><li><a class="nounderline abstract_t">Chen M, Guo Q, Wang Y, et al. Shifts in the Antibiotic Susceptibility, Serogroups, and Clonal Complexes of Neisseria meningitidis in Shanghai, China: A Time Trend Analysis of the Pre-Quinolone and Quinolone Eras. PLoS Med 2015; 12:e1001838; discussion e1001838.</a></li><li><a class="nounderline abstract_t">Zalmanovici Trestioreanu A, Fraser A, Gafter-Gvili A, et al. Antibiotics for preventing meningococcal infections. Cochrane Database Syst Rev 2013; :CD004785.</a></li><li><a class="nounderline abstract_t">McNamara LA, Topaz N, Wang X, et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. MMWR Morb Mortal Wkly Rep 2017; 66:734.</a></li><li><a class="nounderline abstract_t">Applegate AO, Fong VC, Tardivel K, et al. Notes from the Field: Meningococcal Disease in an International Traveler on Eculizumab Therapy - United States, 2015. MMWR Morb Mortal Wkly Rep 2016; 65:696.</a></li><li><a class="nounderline abstract_t">Langereis JD, van den Broek B, Franssen S, et al. Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients. Blood Adv 2020; 4:3615.</a></li><li><a class="nounderline abstract_t">Crew PE, McNamara L, Waldron PE, et al. Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease. J Infect 2020; 80:350.</a></li><li><a class="nounderline abstract_t">Bozio CH, Isenhour C, McNamara LA. Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States. PLoS One 2020; 15:e0241989.</a></li><li><a class="nounderline abstract_t">Katz AR, Chasnoff R, Komeya A, Lee MV. Neisseria meningitidis urethritis: a case report highlighting clinical similarities to and epidemiological differences from gonococcal urethritis. Sex Transm Dis 2011; 38:439.</a></li><li><a class="nounderline abstract_t">Conde-Glez CJ, Calderón E. Urogenital infection due to meningococcus in men and women. Sex Transm Dis 1991; 18:72.</a></li><li><a class="nounderline abstract_t">Andersen J, Berthelsen L, Bech Jensen B, Lind I. Dynamics of the meningococcal carrier state and characteristics of the carrier strains: a longitudinal study within three cohorts of military recruits. Epidemiol Infect 1998; 121:85.</a></li><li><a class="nounderline abstract_t">Block C, Raz R, Frasch CE, et al. Re-emergence of meningococcal carriage on three-year follow-up of a kibbutz population after whole-community chemoprophylaxis. Eur J Clin Microbiol Infect Dis 1993; 12:505.</a></li><li><a class="nounderline abstract_t">Weidmer CE, Dunkel TB, Pettyjohn FS, et al. Effectiveness of rifampin in eradicating the meningococcal carrier state in a relatively closed population: emergence of resistant strains. J Infect Dis 1971; 124:172.</a></li></ol></div><div id="topicVersionRevision">Topic 1274 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11333996" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Meningococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17021322" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical practice. Prevention of meningococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17604802" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemic meningitis, meningococcaemia, and Neisseria meningitidis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9256224" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prognostic factors in meningococcal disease. Development of a bedside predictive model and scoring system. Barcelona Meningococcal Disease Surveillance Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1515827" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Early treatment with parenteral penicillin in meningococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1515826" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Meningococcal infections: reducing the case fatality rate by giving penicillin before admission to hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11354202" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Improving promptness of antibiotic treatment in meningococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17008668" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Meningococcal disease and its management in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17147958" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Meningococcal disease deaths and the frequency of antibiotic administration delays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19191644" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Severity of meningococcal disease associated with genomic bacterial load.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16630316" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Rapid sterilisation of cerebrospinal fluid in meningococcal meningitis: Implications for treatment duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18582342" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27085199" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Corrigendum to "The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent Adults" [J Infect 72 (2016) 405-438].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31140070" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Impact of pre-hospital antibiotic therapy on mortality in invasive meningococcal disease: a propensity score study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32555137" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Detection of Ciprofloxacin-Resistant,β-Lactamase-Producing Neisseria meningitidis Serogroup Y Isolates - United States, 2019-2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34843604" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Antibiotic resistance among invasive Neisseria meningitidis isolates in England, Wales and Northern Ireland (2010/11 to 2018/19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36273639" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Meningococcal disease in North America: Updates from the Global Meningococcal Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35266516" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Antimicrobial Susceptibility Survey of Invasive Neisseria meningitidis, United States 2012-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27733517" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Emergence of meningococci with reduced susceptibility to third-generation cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494903" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Practice guidelines for the management of bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2292206" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ceftriaxone monotherapy for bacterial meningitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8307046" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ceftriaxone versus penicillin G in the short-term treatment of meningococcal meningitis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8307046" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Ceftriaxone versus penicillin G in the short-term treatment of meningococcal meningitis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8363385" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3895175" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prospective comparative trial of ceftriaxone vs. conventional therapy for treatment of bacterial meningitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28847701" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Invasive meningococcal disease: Impact of short course therapy. A DOOR/RADAR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2068463" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Aztreonam in the treatment of gram-negative bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1554823" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Epidemiology and molecular basis of penicillin-resistant Neisseria meningitidis in Spain: a 5-year history (1985-1989).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2896987" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Penicillin-insensitive Neisseria meningitidis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3134848" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Relative penicillin G resistance in Neisseria meningitidis and reduced affinity of penicillin-binding protein 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31434673" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Meropenem-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with known type IV penicillin hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7625802" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2062603" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Imipenem/cilastatin treatment of bacterial meningitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9744970" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : High-level chloramphenicol resistance in Neisseria meningitidis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11577376" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20210367" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Safety considerations of fluoroquinolones in the elderly: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3889396" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Seven days of ceftriaxone therapy is as effective as ten days' treatment for bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3918127" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Persistence of Neisseria meningitidis in the upper respiratory tract after intravenous antibiotic therapy for systemic meningococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4965740" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Attempted prophylaxis against meningococcal infection using intramuscular penicillin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5544138" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prediction of antimeningococcic chemoprophylactic efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16039333" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9690327" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : [Optimizing the response to epidemics of meningococcal meningitis: report of a workshop of experts at CERMES (Niamey, Niger, 12th to 14th January 1998)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12942396" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Three days of intravenous benzyl penicillin treatment of meningococcal disease in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12432041" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Dexamethasone in adults with bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5346629" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Dexamethasone in the treatment of acute bacterial meningitis: the effect of study design on the interpretation of results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20824838" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Corticosteroids for acute bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34303412" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Community-acquired bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28974828" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Does Dexamethasone Helps in Meningococcal Sepsis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11496851" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Dysfunction of endothelial protein C activation in severe meningococcal sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11303270" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Protein C replacement in severe meningococcemia: rationale and clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12794428" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11090052" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12677574" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Surgical interventions in children with meningococcal purpura fulminans--a review of 117 procedures in 21 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19867668" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33417592" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12969927" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Case fatality rates for meningococcal disease in an English population, 1963-98: database study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/252144" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mortality in meningococcal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4965818" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Meningococcal infections at an army training center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9314453" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Meningococcal septic shock in children: clinical and laboratory features, outcome, and development of a prognostic score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16758417" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27235364" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Genome-based study of a spatio-temporal cluster of invasive meningococcal disease due to Neisseria meningitidis serogroup C, clonal complex 11.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18626301" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clinical features, outcome, and meningococcal genotype in 258 adults with meningococcal meningitis: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29509877" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sex Difference in Meningococcal Disease Mortality, New York City, 2008-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6363729" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Landmark article April 24, 1937. The treatment of meningococcic meningitis with sulfanilamide. Preliminary report. By Francis F. Schwentker, Sidney Gelman, and Perrin H. Long.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/823273" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23515099" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23515099" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11089828" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Risk of secondary meningococcal disease in health-care workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10694164" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Seven-week interval between acquisition of a meningococcus and the onset of invasive disease. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2897515" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of group A Neisseria meningitidis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18288075" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Emergence of fluoroquinolone-resistant Neisseria meningitidis--Minnesota and North Dakota, 2007-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246360" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18032423" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Fluoroquinolone resistance in Neisseria meningitidis in Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26057853" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Shifts in the Antibiotic Susceptibility, Serogroups, and Clonal Complexes of Neisseria meningitidis in Shanghai, China: A Time Trend Analysis of the Pre-Quinolone and Quinolone Eras.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24163051" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Antibiotics for preventing meningococcal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28704351" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27414068" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Notes from the Field: Meningococcal Disease in an International Traveler on Eculizumab Therapy - United States, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32766853" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31783062" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33180804" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21150815" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Neisseria meningitidis urethritis: a case report highlighting clinical similarities to and epidemiological differences from gonococcal urethritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1907403" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Urogenital infection due to meningococcus in men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9747759" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Dynamics of the meningococcal carrier state and characteristics of the carrier strains: a longitudinal study within three cohorts of military recruits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8404910" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Re-emergence of meningococcal carriage on three-year follow-up of a kibbutz population after whole-community chemoprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5001453" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effectiveness of rifampin in eradicating the meningococcal carrier state in a relatively closed population: emergence of resistant strains.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
